Yuhan Corporation of South Korea out-licensed rights for its dual agonist NASH treatment to Boehringer Ingelheim in an agreement worth up to $870 million. BI will pay $40 million upfront and as much as $830 million in milestone payments, plus tiered royalties. The pre-clinical treatment is a first-in-class molecule that combines GLP-1 and FGF21 antagonists in a single molecule to reduce liver cell injury and hepatic inflammation by treating steatohepatitis while having direct anti-fibrotic effects.
Source: China Biotoday
